CN105367536A - Novel iridoid and preparation method and medical application thereof - Google Patents
Novel iridoid and preparation method and medical application thereof Download PDFInfo
- Publication number
- CN105367536A CN105367536A CN201510960609.8A CN201510960609A CN105367536A CN 105367536 A CN105367536 A CN 105367536A CN 201510960609 A CN201510960609 A CN 201510960609A CN 105367536 A CN105367536 A CN 105367536A
- Authority
- CN
- China
- Prior art keywords
- preparation
- iridoid
- cell
- compound
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AGXFXMZAPDMEOH-ALGWMNEGSA-N CC(C)CC(OCC([C@@H](C1)[C@@]2(C)[C@@H](CO)C1=O)=CO[C@H]2OC(CC(C)C)=O)=O Chemical compound CC(C)CC(OCC([C@@H](C1)[C@@]2(C)[C@@H](CO)C1=O)=CO[C@H]2OC(CC(C)C)=O)=O AGXFXMZAPDMEOH-ALGWMNEGSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/40—Separation, e.g. from natural material; Purification
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses novel iridoid and a preparation method and medical application thereof, and belongs to the technical field of medicine. The iridoid is reported for the first time, is novel in structure, and can be extracted and separated out of dry whole western Sichuan hearba swertiae mussotii in a purifying mode. It is verified through in vitro tests that the iridoid can restrain the proliferation activity of ovarian cancer cells SKOV3 and influence distribution of the cell cycle, cancer cells are retarded in the G0/G1 cycle, the iridoid can be combined with tyrosine kinase phosphorylation ATP binding sites of an EGFR/HER2 receptor to restrain phosphorylation of the cancer cells, then expression of HER2 and P-HER2 protein is lowered to induce cell apoptosis, and the iridoid can be used for being developed into a drug for treating the ovarian cancer.
Description
Technical field
The invention belongs to technical field of pharmaceuticals, be specifically related to be separated a kind of iridoid obtained from the dry herb of river western long,sharp,protruding teeth dish, containing its pharmaceutical composition and its preparation method and application.
Background technology
Swertia mussotii Franch. SwertiamussotiiFranch. is Gentianaceae Swertia plant, annual herb, high 15 ~ 60cm, all herbal medicine, originate in Tibet, Yunnan (Deqie), Northwest Sichuan, the west and south, Qinghai, be distributed in the hillside of height above sea level 1900 ~ 3000m, river valley, sylvan life, shrubbery, waterside.Swertia mussotii Franch. is used as medicine as " ZANGYINCHEN " always.But, ZANGYINCHEN is the general name of the conventional Tibetan medicine of a class treatment liver and gall diseases, former plant has Swertia mussotii Franch. and Indian Herba Swertiae bimaculatae, and also comprise Gentianaceae Swertia, flower anchor genus, Gentianopsis barbata genus, larynx hair Pittosporum, Marsh Felwort genus, Saxifragaceae Saxifraga several plants, Botanical origin is disorderly.
Swertia mussotii Franch. is used as medicine as " ZANGYINCHEN ", just on the books, with a long history, of many uses, evident in efficacy in the Four-Volume Medical Code, " Jingzhubencao " etc., and this medicinal material is distributed more widely in China, abundance, has good value of exploiting and utilizing.In recent years, take Swertia mussotii Franch. as main raw material, the new drug preparation that processes through modern crafts on the basis of traditional prescription has Jingzhu Gantaishu capsules, anxious proheparinum tablet, YIGANNING sheet, Zhixieling of antidiarrheal, ZANGYINCHEN sheet, eight taste ZANGYINCHEN are loose, 20 Six-element ZANGYINCHEN balls, 13 taste ZANGYINCHEN are loose, safflower seven taste side etc.
In Swertia mussotii Franch., chemical composition is mainly xanthene ketone, iridoid glycosides, triterpenes etc., in addition also containing polysaccharide, volatile oil, mineral substance, steroidal etc.Iridoid glycosides, triterpenes components are the main active ingredient of this genus.Iridoid contained in Swertia mussotii Franch., comprises iridoid and secoiridoid two class, based on secoiridoid.Triterpenes components, based on Triterpenoids sapogenins, mainly contains Oleanolic Acid, ursolic acid etc.The iridoids got from Swertia mussotii Franch. has Swertia mussotii Franch. lactone I, swertiamarin, gentiopicrin, sweroside.Swertiamarin and sweroside are present in the main active ingredient in Swertia plant.
Summary of the invention
The object of this invention is to provide and a kind ofly from the dry herb of river western long,sharp,protruding teeth dish, be separated a kind of iridoid obtained, containing its pharmaceutical composition and its preparation method and application.
Above-mentioned purpose of the present invention is achieved by technical scheme below:
There is the compound (I) of following structural formula:
The preparation method of described compound (I), comprise following operation steps: the dry herb of western for river long,sharp,protruding teeth dish is pulverized by (a), extract with 70 ~ 80% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste, use sherwood oil, ethyl acetate and water saturated n-butanol extraction successively, obtain petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract macroporous resin removal of impurities in (b) step (a), first use 10% ethanol elution, 6 column volumes, then use 70% ethanol elution, 8 column volumes, collect 70% elutriant, concentrating under reduced pressure obtains 70% ethanol elution enriched material; C in () step (b), 70% ethanol elution enriched material purification on normal-phase silica gel is separated, obtain 5 components successively with the methylene chloride-methanol gradient elution that volume ratio is 85:1,50:1,25:1,10:1 and 1:1; D in () step (c), component 4 is separated further by purification on normal-phase silica gel, obtain 3 components successively with the methylene chloride-methanol gradient elution that volume ratio is 15:1,10:1 and 5:1; E in () step (d), component 2 reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 70%, collect 8 ~ 12 column volume elutriants, elutriant concentrating under reduced pressure obtains pure compound (I).
Further, in step (a), extract with 75% alcohol heat reflux, united extraction liquid.
Further, described macroporous resin is D101 type macroporous adsorbent resin.
A kind of pharmaceutical composition, the described compound (I) wherein containing treatment significant quantity and pharmaceutically acceptable carrier.
The application of described compound (I) in the medicine of preparation treatment ovarian cancer.
The application of described pharmaceutical composition in the medicine of preparation treatment ovarian cancer.
When the compounds of this invention is used as medicine, directly can uses, or use with the form of pharmaceutical composition.
This pharmaceutical composition contains the compounds of this invention (I) for the treatment of significant quantity, and all the other are acceptable on pharmacology, nontoxic to humans and animals and pharmaceutically acceptable carrier of inertia and/or vehicle.
Described pharmaceutically acceptable carrier or vehicle are that one or more are selected from solid, semisolid and liquid diluent, filler and pharmaceutical preparation assistant agent.Pharmaceutical composition of the present invention is used with the form of per weight dose.Medicine of the present invention is applied to by form that is oral or injection the patient needing treatment.For time oral, tablet, slow releasing tablet, controlled release tablet, capsule, dripping pill, micropill, suspensoid, emulsion, powder or granule, oral liquid etc. can be made into; During for injecting, can be made into water-based or oily solution, aseptic powder injection, liposome or the emulsion etc. of sterilizing.
Accompanying drawing explanation
Fig. 1 is compound (I) structural formula;
Fig. 2 is that compound (I) calculates ECD and experiment ECD figure.
Embodiment
Further illustrate essentiality content of the present invention below in conjunction with embodiment, but do not limit scope with this.Although be explained in detail the present invention with reference to preferred embodiment, those of ordinary skill in the art should be appreciated that and can modify to technical scheme of the present invention or equivalent replacement, and does not depart from essence and the scope of technical solution of the present invention.
Main raw, reagent source and instrument type:
Ethanol, sherwood oil, ethyl acetate, propyl carbinol, methylene dichloride are analytical pure, and purchased from Shanghai Ling Feng chemical reagent company limited, methyl alcohol, analytical pure, purchased from Jiangsu Han Bang chemical reagent company limited.
Embodiment 1: compound (I) is separated preparation and structural identification
A the dry herb (10kg) of () river western long,sharp,protruding teeth dish is pulverized, (30L × 3 time) are extracted with 75% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste (6L), use sherwood oil (6L × 3 time), ethyl acetate (6L × 3 time) and water saturated propyl carbinol (6L × 3 time) to extract successively, obtain petroleum ether extract, acetic acid ethyl ester extract (381g) and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract D101 macroporous resin removal of impurities in (b) step (a), first use 10% ethanol elution, 6 column volumes, use 70% ethanol elution, 8 column volumes again, collect 70% elutriant, concentrating under reduced pressure obtains 70% ethanol elution enriched material (131g); C in () step (b), 70% ethanol elution enriched material purification on normal-phase silica gel is separated, successively with volume ratio be 85:1 (8 column volumes), the methylene chloride-methanol gradient elution of 50:1 (8 column volumes), 25:1 (8 column volumes), 10:1 (10 column volumes) and 1:1 (8 column volumes) obtains 5 components; D component 4 (27g) is separated further by purification on normal-phase silica gel in () step (c), successively with volume ratio be 15:1 (8 column volumes), the methylene chloride-methanol gradient elution of 10:1 (8 column volumes) and 5:1 (6 column volumes) obtains 3 components; E in () step (d), component 2 (18g) reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 70%, collect 8 ~ 12 column volume elutriants, elutriant concentrating under reduced pressure obtains pure compound (I) (230mg).
Structural identification: colorless oil; HR-ESIMS shows [M+Na]
+for m/z405.1914, can obtain molecular formula in conjunction with nuclear-magnetism feature is C
20h
30o
7, degree of unsaturation is 6.Hydrogen nuclear magnetic resonance modal data δ
h(ppm, DMSO-d
6, 600MHz): H-1 (5.76, d, J=5.4), H-3 (6.25, s), H-5 (2.78, dd, J=15.0, 7.8), H-6 (1.96, m), H-6 (2.21, m), H-8 (1.98, m), H-9 (2.28, ddd, J=10.0, 5.0, 5.0), H-10 (3.65, dd, J=13.5, 8.5), H-10 (3.82, dd, J=13.5, 8.5), H-11 (4.24, d, J=15.0), H-11 (4.47, d, J=15.0), H-2 ' (2H, 2.09, dd, J=8.5, 4.5), H-3 ' (2.01, m), H-4 ' (0.91, d, J=4.5), H-5 ' (0.91, d, J=4.5), H-2 " (2H, 2.07, d, J=9.0), H-3 " (2.00, m), H-4 " (0.89, d, J=5.5), H-5 " (0.89, d, J=5.5), carbon-13 nmr spectra data δ
c(ppm, DMSO-d
6, 150MHz): 90.8 (CH, 1-C), 139.9 (CH, 3-C), 112.6 (C, 4-C), 32.0 (CH, 5-C), 41.1 (CH
2, 6-C), 218.7 (C, 7-C), 52.8 (CH, 8-C), 39.3 (CH, 9-C), 61.0 (CH
2, 10-C), 63.1 (CH
2, 11-C), 171.6 (C, 1 '-C), 42.8 (CH
2, 2 '-C), 25.1 (CH, 3 '-C), 21.8 (CH
3, 4 '-C), 21.8 (CH
3, 5 '-C), 172.7 (C, 1 "-C), 43.0 (CH
2, 2 " and-C), 25.2 (CH, 3 "-C), 21.7 (CH
3, 4 " and-C), 21.7 (CH
3, 5 " and-C), carbon atom mark is see Fig. 1.IR spectrum shows that this compound contains hydroxyl, carbonyl and alkene structures (3312cm
-1, 1748cm
-1and 1665cm
-1).
1hNMR spectrum shows two isovaleryl structures [δ H2.09 (dd, J=8.5,4.5Hz; H-2 '), 2.01 (m, H-3 '); 0.91 (d, J=4.5Hz, H-4 '); 0.91 (d, J=4.5Hz, H-5 '); 2.07 (d, J=9.0Hz, H-2 "); 2.00 (m; H-3 "), 0.89 (d, J=5.5Hz; H-4 "); 0.89 (d, J=5.5Hz, H-5 ")]; and an olefinic proton signal [δ H6.25 (s, H-3)].
13cNMR spectrum shows 20 carbon signals, comprise four methyl signals [δ C21.8 (C-4 '), 21.8 (C-5 '), 21.7 (C-4 ") and 21.7 (C-5 ")], five methylene radical [two containing oxygen δ C61.0 (C-6) and 63.1 (C-11)], [one containing oxygen δ C90.8 (C-1) for seven methynes, one containing oxygen alkene methyne δ C139.9 (C-3)] and four quaternary carbon [alkene quaternary carbon δ C112.6 (C-4), ketone carbonyl δ C218.7 (C-7), two ester carbonyl group δ C171.6 (C-1 ') and 172.7 (C-1 ")].In HMBC spectrum, H-1 (δ H5.76) and H
2-2 ' (δ H2.09) and C-1 ' (δ C171.6), and H
2-11 (δ H4.47,4.24), H
2-2 " (δ H2.07) and H-3 " (δ H2.00) and C-1 " dependency of (δ C172.7) indicates two isovaleryl and is connected respectively at C-1 with C-11.In ROESY spectrum, the intersection peak of H-10 β and H-9, H-9 and H-5, H-9 and H-6 β, H-5 and H-6 β shows that H-5 and H-9 is beta comfiguration; The dependency of H-1 and H-8 and H-6 α shows that H-1 and H-8 is α configuration.Comprehensive hydrogen spectrum, carbon spectrum, HMBC spectrum and ROESY spectrum, and document is about correlation type nuclear magnetic data, can substantially determine this compound as shown in Figure 1, steric configuration is determined further by ECD test, theoretical value and experimental value basically identical (Fig. 2).
Embodiment 2: compound (I) pharmacological action is tested
One, material and instrument
People's serous papillary cystenoma of ovary shape cystadenocarcinoma Cell line SKOV3 is provided by the Medical experimental center of Lanzhou University.General RPMI-1640 substratum (10% foetal calf serum) is cultivated.Compound (I) is made by oneself, and HPLC normalization method purity is greater than 98%.RPMI-1640 nutrient solution, tetramethyl-azo frustrate indigo plant (MTT), dimethyl sulfoxide (DMSO) (DMSO), L-glutaminate Ke Hao biotechnology company limited.Trypsinase is purchased from Sigma Co., USA.Foetal calf serum is purchased from Hangzhou Sijiqing Biological Engineering Material Co., Ltd..Ten Second Academys base sodium sulfonate (SDS) are purchased from Xi'an Zhou Ding biotechnology limited liability company.HER2 (FITC mark) is purchased from Beijing Bo Aosen Bioisystech Co., Ltd.Acidifying HER2 (FITC mark) is purchased from Beijing Bo Aosen Bioisystech Co., Ltd.Penicillin, Streptomycin sulphate are purchased from North China Pharmaceutical Factory.
CO
2incubator (Heraeus, BB5060UV), Germany inverted phase contrast microscope (OLYMPUS, CK-40), Japan fluorescent microscope (OLYMPUSOPTICAL, A × 80, Japan), Bechtop (Purifying Equipment Co., Ltd., Suzhou), enzyme micro-plate reader (BIO-TEK company, the U.S.), low-temperature and high-speed whizzer (Beckman-Coulter company, Germany), EpicsXL flow cytometer (Beckman-Coulter company, Germany), the automatic desk-top flash arrestor (Xinhua Medical Apparatus Co., Ltd. Shandong) of R-3850 type, DHG-9245A type electric heating constant-temperature blowing drying box (Shanghai-permanent Science and Technology Ltd.), KQ-250DB type numerical control ultrasonic cleaner (Kunshan Ultrasonic Instruments Co., Ltd.), digital display constant water bath box (Shanghai Mei Xiang Instrument Ltd.), BS400S electronic molecules balance (Beijing Sai Duolisi balance company limited), 08-2 constant temperature blender with magnetic force (Shanghai balance equipment factory), TDL-5 generic centrifuge (Anting Scientific Instrument Factory, Shanghai), cryogenic refrigerator (SANYO GS company), electronics ice making case (SANYO GS company), cell cryopreservation tube (Shanghai Sheng Gong biotechnology company limited), 96 orifice plates (Ke Hao biotechnology company limited).
Two, test method
1, cell cultures
1.1 cell recovery
Put into 37 DEG C of warm water immediately after being taken out from liquid nitrogen rapidly by cryopreservation tube, rock cryopreservation tube gently, frozen thing is dissolved as early as possible, put it in Bechtop, cell suspension in it is moved into centrifuge tube, then in centrifuge tube, adds 10 times of RPMI-1640 nutrient solutions (containing 10% calf serum), centrifugal, 800rpm/min, centrifugal 5 ~ 10min, abandons supernatant, adds the RPMI-1640 nutrient solution containing 10% calf serum in cell precipitation, jog is even, puts 37 DEG C, 5%CO
2cultivate in the incubator of concentration.And indicate Cell Name and date.
1.2 passages are cultivated
When SKOV3 cell grows to 80 ~ 90% culturing bottle, discard original nutrient solution, and wash twice with the PBS prepared; With the trysinization of 0.25%, observe under being placed on inverted microscope, when seeing that cell retraction, intercellular substance increase, form become bowlder and discard Digestive system, add in a certain amount of nutrient solution and trysinization liquid, and the cell digested is blown and beaten gently with suction pipe., make it depart from culturing bottle, the centrifugal 5min of 800rpm/min, abandons supernatant; On tally, carry out cell counting under microscope, go down to posterity in 1:3 ratio, divide and be filled in culturing bottle, continue to cultivate after again supplementing appropriate nutrient solution.Note strict aseptic technique, every day observation of cell growing state.
1.3 cell cryopreservation
The cell of taking the logarithm vegetative period is with centrifugal after the tryptic digestion of 0.25%, PBS washes 2 times, the centrifugal 5min of l000rpm on low speed centrifuge, abandon supernatant liquor, add the cells frozen storing liquid containing DMSO of 1mL precooling at-20 DEG C, moving in cryopreservation tube with after suction pipe piping and druming evenly, with putting into 4 DEG C of standing 30min after sealed membrane sealing mark, proceeding to-80 DEG C after-20 DEG C of placement 2h afterwards.The cell used in one month can be stored in-80 DEG C, should move in liquid nitrogen after long-term preserver 24h by-80 DEG C.The recovery of cell and the frozen principle that should follow are melted soon for freezing slowly.
2, tetramethyl-azo blue (MTT) experiment
(1), when selecting cell (the growth 80-90%) of logarithmic phase, with 0.25% pancreatin prepared, cell is disappeared.Change well, single cell suspension is made in piping and druming lightly, and the final cell concn of adjustment is 8 × 10
4/ mL; (2) get 3 96 orifice plates, each time point 1 plate, 100 μ L/ holes, every porocyte number is 10
4carry out grouping mark; (3) divide into groups after cell attachment, if blank group (not inoculating cell), control group (only containing equivalent solvent) and experimental group (add the compound (I) of different concns, its final concentration is respectively 0.1,1,10,20,30 and 60 μm of ol/L), often group establishes 6 multiple holes; (4) 37 DEG C, 5%CO
224,48 and 72h is cultivated respectively under condition; (5), after the time arrives, after sucking supernatant liquor, every hole adds the MTT10 μ L of 5g/L; (6) add 10 μ LDMSO after cultivating 4h, multi-functional microplate test macro measures each hole optical density(OD) OD value with 490nm wavelength; (7) medicine is to the calculating of cell inhibitory rate:
Inhibiting rate (%)=(cellular control unit number-experimental group cell count)/cellular control unit number × 100%.
Experiment at least in triplicate.
3, PI staining flow cytometry (FCM) detects cell cycle and apoptosis
(1) the SKOV3 cell of taking the logarithm vegetative period, first make single cell suspension with blowing and beating gently after the trysinization prepared, adjustment cell concn is 6 × 10
5/ mL; (2) with 6 × 10
5the density of/mL is inoculated in the culturing bottle of 50mL, in 37 DEG C, 5%CO
224h is cultivated in incubator; (3) after 24h by original nutrient solution sucking-off, add isodose (7.5mL), containing the nutrient solution of the compound (I) of different concns (0,10,20 and 30 μm of ol/L), continue at 37 DEG C, 5%CO
248h is cultivated in incubator; (4) collecting cell after 48h, makes single cell suspension, after being moved into centrifuge tube with blowing and beating gently after 0.25% trysinization, centrifugal with 1000r/min, centrifugal l0min, abandoning supernatant, and fix with the ice ethanol of 4 DEG C 70%, place the refrigerator overnight of 4 DEG C; (5) secondary daily phosphate buffered saline buffer PBS clean, centrifugal, detect after abandoning supernatant and add rnase (RNAase) 150 μ L and propidium iodide (PI) dye liquor 150 μ L, lucifuge dyeing 30min at ambient temperature, uses period profile and the apoptosis situation of flow cytomery cell.Test in triplicate, and application software is analyzed.
4, PI staining flow cytometry (FCM) detects the expression rate of HER2, P-HER2 albumen
(1) the SKOV3 cell of taking the logarithm vegetative period, first make single cell suspension with blowing and beating gently after 0.25% trysinization, adjustment cell concn is l × 10
6/ mL; (2) with l × 10
6the density of/mL is inoculated in the culturing bottle of 50mL, in 37 DEG C, 5%CO
224h is cultivated in incubator; (3) the original nutrient solution of sucking-off after 24h, the nutrient solution (control group) of the nutrient solution (experimental group) of compound (I) that add isodose (12.5mL), that containing concentration be 20 μm of ol/L and not drug containing, continues at 37 DEG C, 5%CO
248h is cultivated in incubator; (4) collecting cell after 48h, first moves into the nutrient solution in culturing bottle in centrifuge tube, then uses the tryptic digestion of 0.25%, and the cell in guarantee culturing bottle and nutritive medium all move into centrifuge tube, centrifugal by 1000r/min, l0min; (5) add PBS again by the centrifugal 10min of 1000 turns/min, repeat twice; (6) treat in test tube, there are 100 μ L samples, add HER2, P-HER2 antibody receptor (dissolve with the PBS of PH=7.4,0.01M, and press 1:60 dilution) of 30 μ LFITC marks to experimental group and control group respectively, hatch 30min for 4 DEG C; (7) cell washing lotion is added, 1200 turns/min, 10min low-temperature centrifugation, 2 times repeatedly, censorship after removal supernatant; (8) expression rate of HER2, P-HER2 albumen of flow cytomery SKOV3 cell.Above-mentioned experimental procedure in triplicate.
5, data analysis
Adopt the software of SPSS17.0 to carry out statistical analysis, represent with mean ± standard deviation (X ± s).Adopt one-way analysis of variance to compare measurement data, and compare employing LSD inspection between group between two, the comparison of rate adopts chi square test, is that difference has statistical significance with P<0.05.
Three, result and conclusion
1, MTT experiment result
All occur obvious cell inhibitory effect effect after the compound (I) of different concns acts on people's adenocarcinoma ovaries SKOV3 cell 24,48 and 72h, show as OD value (absorbance A570) and reduce, inhibiting rate raises; Result between different concns group is variant, and difference has statistical significance (P<0.05), also significant difference (P<0.05) is had different action time, show that compound (I) propagation to ovarian cancer SKOV3 cell is inhibited, and its inhibiting rate is concentration and time-dependent manner.Learnt by experimental result, when concentration is 20 μm of ol/L, effect is more satisfactory.The results are shown in Table 1.
2, PI staining flow cytometry (FCM) detects the result of cell cycle
The compound (I) choosing different concns (10,20,30 μm of ol/L) acts on SKOV348h, and experimental group comparatively control group compares G
0/ G
1cell quantity in increasing trend, and S phase and G
2/ M cell quantity is minimizing trend, and when being 20 μm of ol/L with compound (I) concentration, effect is the most obvious.Compared with control group, each experimental group has statistical significance (P<0.05).G after each experimental group effect 48h
0/ G
1cell quantity be respectively 10 μm of ol/L groups (60.707 ± 2.382), 20 μm of ol/L groups (69.611 ± 2.366), 30 μm of ol/L groups (61.099 ± 1.577), the analysis showed that 30 μm of ol/L groups are compared with 10 μm of ol/L, no significant difference (P=0.809), comparing difference between all the other each concentration groups all has statistical significance (P<0.05).After each experimental group effect 48h, the cell quantity of S phase is respectively l0 μm of ol/L group (24.254 ± 3.244), 20 μm of ol/L groups (19.468 ± 0.580), 30 μm of ol/L groups (17.743 ± 1.311), wherein 30 μm of ol/L groups are compared with 20 μm of ol/L groups, no significant difference (P=0.305), all the other each concentration groups compare difference statistical significance (P<0.05).G after each experimental group effect 48h
2the cell quantity of/M phase is respectively l0 μm of ol/L group (13.276 ± 0.658), 20 μm of ol/L groups (10.624 ± 0.483), 30 μm of ol/L (21.147 ± 2.865), and comparing difference between remaining each concentration group has statistical significance (P<0.05).It can thus be appreciated that the effect that the compound of 20 μm of ol/L (I) acts on SKOV348h is best, by cell-cycle arrest in G
0/ G
1phase, make it can not enter the S phase.The results are shown in Table 2 (note: compared with control group, equal P<0.05; * G
0/ G
1during the phase, 30 μm of ol/L groups are compared with 10 μm of ol/L groups, no significant difference (P=0.809), and during S phase, 30 μm of ol/L are compared with 20 μm of ol/L, no significant difference (P=0.305); All the other G
0/ G
1, S, G
2compare between each phase group of/M, equal P<0.05.)。
3, PI staining flow cytometry (FCM) detects the expression of HER2, P-HER2
The expression of flow cytomery SKOV3 cell HER2 and P-HER2 on its surface before and after application compound (I), learn that compound (I) action effect of 20 μm of ol/L is ideal from above-mentioned experimental result, therefore this step adopts compound (I) (20 μm of ol/L) to act on SKOV3 cell 48h, the change not obvious (P=0.13) of HER2 protein expression before and after result display application compound (I), and the expression of P-HER2 albumen has obvious difference (P<0.05).The results are shown in Table 3 (note: compared with control group, * P=0.13,
#p<0.05).
Conclusion, compound (I) can suppress the proliferation activity of ovarian cancer SKOV3 cell, and the result of this experiment MTT shows, and it affects the distribution of cell cycle, and tumour cell is arrested in G
0/ G
1phase, simultaneously by being combined with the tyrosine kinases phosphorylate ATP-binding site of EGFR/HER2 acceptor, suppress its phosphorylation, and then the expression of lowering HER2, P-HER2 albumen carrys out cell death inducing.
Table 1 different concns, the compound (I) of different action time are on the impact of SKOV3 cell
The compound (I) of table 2 different concns acts on the impact of SKOV3 cell 48h cell cycle distribution
The compound (I) of table 320 μm ol/L acts on the expression of HER2, P-HER2 after SKOV3 cell 48h
Embodiment 3
The preparation of tablet: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, vehicle is added, pelletizing press sheet than the ratio for 1:7 in itself and excipient weight.
Embodiment 4
The preparation of oral liquid: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, oral liquid method for making makes oral liquid routinely.
Embodiment 5
The preparation of capsule or granule: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, add vehicle in itself and excipient weight than the ratio for 1:9, make capsule or granule.
Embodiment 6
The preparation of injection liquid: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, inject with water routinely, essence filter, injection liquid is made in embedding sterilizing.
Embodiment 7
The preparation of aseptic powder injection: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, be dissolved in sterile water for injection, stirring makes molten, filter with aseptic suction funnel, aseptic essence filter again, be sub-packed in ampoule, after frozen drying, aseptic sealing by fusing obtains powder injection.
The effect of above-described embodiment is essentiality content of the present invention is described, but does not limit protection scope of the present invention with this.Those of ordinary skill in the art should be appreciated that and can modify to technical scheme of the present invention or equivalent replacement, and does not depart from essence and the protection domain of technical solution of the present invention.
Claims (7)
1. there is the compound (I) of following structural formula:
2. the preparation method of compound according to claim 1 (I), it is characterized in that comprising following operation steps: the dry herb of western for river long,sharp,protruding teeth dish is pulverized by (a), extract with 70 ~ 80% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste, use sherwood oil, ethyl acetate and water saturated n-butanol extraction successively, obtain petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract respectively; B in () step (a), the removal of impurities of thing macroporous resin got by propyl carbinol, first use 10% ethanol elution, 6 column volumes, then use 70% ethanol elution, 8 column volumes, collect 70% elutriant, concentrating under reduced pressure obtains 70% ethanol elution enriched material; C in () step (b), 70% ethanol elution enriched material purification on normal-phase silica gel is separated, obtain 5 components successively with the methylene chloride-methanol gradient elution that volume ratio is 85:1,50:1,25:1,10:1 and 1:1; D in () step (c), component 4 is separated further by purification on normal-phase silica gel, obtain 3 components successively with the methylene chloride-methanol gradient elution that volume ratio is 15:1,10:1 and 5:1; E in () step (d), component 2 reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 70%, collect 8 ~ 12 column volume elutriants, elutriant concentrating under reduced pressure obtains pure compound (I).
3. the preparation method of compound according to claim 2 (I), is characterized in that: in step (a), extracts, united extraction liquid with 75% alcohol heat reflux.
4. the preparation method of compound according to claim 2 (I), is characterized in that: described macroporous resin is D101 type macroporous adsorbent resin.
5. a pharmaceutical composition, is characterized in that: the compound according to claim 1 (I) wherein containing treatment significant quantity and pharmaceutically acceptable carrier.
6. the application of compound according to claim 1 (I) in the medicine of preparation treatment ovarian cancer.
7. the application of pharmaceutical composition according to claim 5 in the medicine of preparation treatment ovarian cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510960609.8A CN105367536A (en) | 2015-12-18 | 2015-12-18 | Novel iridoid and preparation method and medical application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510960609.8A CN105367536A (en) | 2015-12-18 | 2015-12-18 | Novel iridoid and preparation method and medical application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105367536A true CN105367536A (en) | 2016-03-02 |
Family
ID=55370224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510960609.8A Pending CN105367536A (en) | 2015-12-18 | 2015-12-18 | Novel iridoid and preparation method and medical application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105367536A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105481874A (en) * | 2015-12-22 | 2016-04-13 | 陈杰 | Novel diterpene compound for treating ovarian cancer |
| CN105777682A (en) * | 2016-03-23 | 2016-07-20 | 钱浩 | Citicoline sodium medicine composition and pharmaceutical application of citicoline sodium medicine composition to preventing and treating ovarian cancer |
| CN106146291A (en) * | 2016-07-04 | 2016-11-23 | 郑飞珍 | A kind of new sesquiterpene carboxylic acid compound and preparation method thereof and medical usage |
| CN106588948A (en) * | 2016-12-16 | 2017-04-26 | 成都中医药大学 | Oxygen bridge cycloalkene ether terpenoid and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101829080A (en) * | 2010-03-17 | 2010-09-15 | 中国人民解放军第二军医大学 | Application of iridoid compound to preparation of ovarian cancer resistance medicament |
| CN102138966A (en) * | 2010-01-29 | 2011-08-03 | 天津药物研究院 | Tibetan capillaris extract and preparation method, pharmaceutical composition and use thereof |
| CN104387362A (en) * | 2014-11-05 | 2015-03-04 | 浙江中医药大学 | Iridoid ester compounds, and preparation method and application thereof |
-
2015
- 2015-12-18 CN CN201510960609.8A patent/CN105367536A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102138966A (en) * | 2010-01-29 | 2011-08-03 | 天津药物研究院 | Tibetan capillaris extract and preparation method, pharmaceutical composition and use thereof |
| CN101829080A (en) * | 2010-03-17 | 2010-09-15 | 中国人民解放军第二军医大学 | Application of iridoid compound to preparation of ovarian cancer resistance medicament |
| CN104387362A (en) * | 2014-11-05 | 2015-03-04 | 浙江中医药大学 | Iridoid ester compounds, and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 冯焕荣: "新型靶向药物拉帕替尼对人卵巢癌细胞SKOV的影响", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105481874A (en) * | 2015-12-22 | 2016-04-13 | 陈杰 | Novel diterpene compound for treating ovarian cancer |
| CN105777682A (en) * | 2016-03-23 | 2016-07-20 | 钱浩 | Citicoline sodium medicine composition and pharmaceutical application of citicoline sodium medicine composition to preventing and treating ovarian cancer |
| CN106146291A (en) * | 2016-07-04 | 2016-11-23 | 郑飞珍 | A kind of new sesquiterpene carboxylic acid compound and preparation method thereof and medical usage |
| CN106588948A (en) * | 2016-12-16 | 2017-04-26 | 成都中医药大学 | Oxygen bridge cycloalkene ether terpenoid and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105330716A (en) | New withanolides compound, and preparation method and medical application thereof | |
| CN105330717A (en) | Novel triterpenoid and preparation method and medical application thereof | |
| CN105153084A (en) | Novel diterpene compound as well as preparation method and medicinal application thereof | |
| CN105367536A (en) | Novel iridoid and preparation method and medical application thereof | |
| CN105943532A (en) | Application of diterpenoid compound to preparation of medicament for treating liver cancer | |
| CN105218489A (en) | A kind of assorted terpene compound newly and preparation method thereof and medicinal use | |
| CN105418539A (en) | New meroterpenoid compound as well as preparation method and pharmaceutical application thereof | |
| CN105418562A (en) | Diterpenoid compound used for treating the prostatic cancer and preparation method therefor | |
| CN105294665A (en) | Novel diterpene compound for neuroprotection | |
| CN105237380A (en) | Triterpene compound used for treating ovarian cancer and preparation method of triterpene compound | |
| CN106008543A (en) | Novel diterpenoid compound and preparation method thereof | |
| CN105130935A (en) | New diterpenoid compounds for treating ovarian cancer | |
| CN105348223A (en) | Novel sesquiterpenoid and preparation method and medical application thereof | |
| CN105481876A (en) | Diterpene compound for treating ovarian cancer | |
| CN102603856B (en) | Anti-tumor saponin in anemone plants and preparation method thereof as well as application | |
| CN105481874A (en) | Novel diterpene compound for treating ovarian cancer | |
| CN105503782A (en) | Protoilludanes type sesquiterpenoid compound and preparation method and medical application thereof | |
| CN106397369A (en) | Novel labdane-type diterpenoid compound, preparation method and application thereof, pharmaceutical composition and application of pharmaceutical composition | |
| CN105523937A (en) | Diterpene compound with medical application and preparation method thereof | |
| CN105622629A (en) | Kaurane type diterpenoid compound for treating prostatic cancer | |
| CN105198897A (en) | New kaurane diterpenoid compound, preparation method and medical application of compound in treating liver cancer | |
| CN105534968A (en) | Application of diterpenoid compound to preparation of drug for treating prostate cancer | |
| CN106074499A (en) | The application in medicine of a kind of Crow alkane type diterpene-kind compound | |
| CN105503990A (en) | Novel withanolides compound as well as preparation method and medical application thereof | |
| CN105198844A (en) | Novel limonin compound as well as preparation method and medical application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160302 |